TENX vs UTHR
TENX: A Phase 3 development-stage pharmaceutical company developing novel cardiopulmonary therapies, primarily levosimendan for pulmonary hypertension and imatinib for pulmonary arterial hypertension. UTHR: United Therapeutics is a rare disease specialist dominating pulmonary hypertension treatment through multiple treprostinil delivery formats while pursuing organ manufacturing innovation as a public benefit corporation.
Side-by-side fundamentals
| Metric | TENX | UTHR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $14.79 | $527.07 | |
| Market cap as of 2026-07-23 | $418M | $22.7B | |
| P/E as of 2026-07-23 | n/a | 17.63 | |
| PEG as of 2026-07-23 | n/a | 2.43 | |
| Net margin as of 2026-07-23 | -10115.8% | +40.6% | UTHR higher |
| Gross margin as of 2026-07-23 | +100.0% | +86.6% | TENX higher |
| Operating margin as of 2026-07-23 | -10390.5% | +45.3% | UTHR higher |
| ROE as of 2026-07-23 | -56.3% | +19.2% | UTHR higher |
| ROA as of 2026-07-23 | -53.1% | +17.3% | UTHR higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -82.9% | +5.9% | UTHR higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +18.0% | |
| Beta as of 2026-07-23 | 0.95 | 0.56 | |
| 1-year return as of 2026-07-22 close | +145.7% | +76.9% | TENX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.